Format

Send to

Choose Destination
Breast Cancer Res Treat. 2017 Jun;163(3):635. doi: 10.1007/s10549-017-4209-5. Epub 2017 Mar 21.

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.

Author information

1
University Basel, Basel, Switzerland. klazien.matter@unibas.ch.
2
Swiss Group of Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland. klazien.matter@unibas.ch.
3
University Basel, Basel, Switzerland.
4
Swiss Group of Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland.
5
University Hospital Z├╝rich, 8091, Zurich, Switzerland.
PMID:
28321586
DOI:
10.1007/s10549-017-4209-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center